To observe effects of Taohong Qizhu Ruangan Decoction on treating liver fibrosis of rats, and effects on TGF-β/Smad signal pathway.Methods:A total of 105 Wistar rats were randomly divided into blank group, model group, control group (colchicine and Fuzheng Huayu Capsule group), Taohong Qizhu Ruangan Decoction group (low dose group, middle dose group, high dose group).Except blank group, the liver fibrosis model was established by the intraperitoneal injection of 50% CCl4 1 mL/kg of olive oil solution at 3, 6, 9 week.At the same time, HE staining and Masson staining were used to observe the pathological expressions of liver fibrosis.The expressions of E-Cadherin, Vimentin, TGF-β1 and Smad2 in liver tissues were detected by immunohistochemistry.The mRNA expressions of E-Cadherin, Vimentin, TGF-β1 and Smad2 in liver tissues were detected by RT-PCR.Results:The pathological results of liver fibrosis showed that with the prolongation of modeling and administration time, each drug-administered group could significantly block the progression of hepatic fibrosis in model rats.And compared with model group, effect of high dose Taohong Qizhu Ruangan Decoction group was most obvious.Immunohistochemical：From 3 week to 9 week, compared with model group, E-cadherin expression was significantly increased than other groups (P<0.05), and there were no differences between groups (P>0.05); compared with model group, TGF-β expression decreased significantly in other drug groups (P<0.05), and there were no differences between groups (P>0.05).RT-PCR：Compared with the blank group, Smad2 mRNA expression in model group significantly increased (P<0.05).Vimentin mRNA and Smad2 mRNA expression of low dose group of Taohong Qizhu Ruangan Decoction significantly decreased (P<0.05).Smad2 mRNA expression of middle dose group of Taohong Qizhu Ruangan Decoction decreased (P<0.05); TGF-β mRNA, Vimentin mRNA expression of Fuzheng Huayu Capsule group decreased compared with the model group (P<0.05).Conclusion:Taohong Qizhu Ruangan Decoction can regulate epithelial-mesenchymal transition through TGF-β/Smad signaling pathway to treat liver fibrosis.